{
    "clinical_study": {
        "@rank": "9817", 
        "arm_group": [
            {
                "arm_group_label": "Dose adjust group (NFAT)", 
                "arm_group_type": "Experimental", 
                "description": "Within 2 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is <15%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 80% the CNI daily dose will be increased by 15%."
            }, 
            {
                "arm_group_label": "Standard of care group", 
                "arm_group_type": "No Intervention", 
                "description": "A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare two different ways of monitoring the immune system\n      to determine how to manage the doses of anti-rejection medications."
        }, 
        "brief_title": "NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Transplantation", 
        "detailed_description": {
            "textblock": "This is a single center randomized controlled trial investigating the efficacy and safety of\n      adjusting calcineurin inhibitor (CNI) dosing based on Nuclear Factor of Activating T Cells\n      (NFAT)-dependent cytokine gene expression as compared to standard of care adjustments based\n      on trough level.  Before any study-related evaluations are performed, the patient must give\n      written informed consent. Once consent is obtained, a patient's eligibility to participate\n      in the study will be assessed within 2 weeks of their 6 month management biopsy.\n      Approximately 40 patients who meet inclusion criteria will be randomized at University of\n      California, San Francisco (UCSF). Eligible patients include any patient maintained on triple\n      therapy with tacrolimus, mycophenolate mofetil ,and prednisone who has had no prior\n      rejection episodes and who has undergone a 6 month management kidney biopsy that shows no\n      evidence of acute cellular rejection or antibody mediated rejection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:  Eligible patients include any patient maintained on triple therapy\n        with tacrolimus, mycophenolate mofetil ,and prednisone who has had no prior rejection\n        episodes and who has undergone a 6 month management kidney biopsy that shows no evidence\n        of acute cellular rejection or antibody mediated rejection.\n\n        Exclusion Criteria: Any patient not maintained on triple therapy with tacrolimus,\n        mycophenolate mofetil and steroids and/or who had evidence of rejection on 6- month\n        management biopsy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771705", 
            "org_study_id": "NFAT dependent cytokines"
        }, 
        "intervention": {
            "arm_group_label": "Dose adjust group (NFAT)", 
            "description": "If the average residual expression of the 3 cytokines is <15%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 80% the CNI daily dose will be increased by 15%.", 
            "intervention_name": "Dose adjust group (NFAT)", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Transplantation", 
            "Kidney", 
            "calcineurin inhibitor", 
            "NFAT", 
            "tacrolimus"
        ], 
        "lastchanged_date": "May 3, 2013", 
        "location": {
            "contact": {
                "email": "Flavio.Vincenti@ucsfmedctr.org", 
                "last_name": "Flavio Vincenti, M.D.", 
                "phone": "415-353-1322"
            }, 
            "contact_backup": {
                "email": "Allison.Webber@ucsfmedctr.org", 
                "last_name": "Allison Webber, M.D.", 
                "phone": "415-353-1290"
            }, 
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94143"
                }, 
                "name": "University of California, San Francisco"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients", 
        "overall_official": [
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Flavio Vincenti, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Allison Webber, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "\u2022Number of adjustments made to tacrolimus regimen at 6 months;  \u2022Lack of correlation between NFAT-dependent cytokine expression and tacrolimus trough levels", 
            "safety_issue": "Yes", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771705"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "19398376", 
                "citation": "Giese T, Sommerer C, Zeier M, Meuer S. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol. 2009 Sep;132(3):305-11. doi: 10.1016/j.clim.2009.03.520. Epub 2009 Apr 23."
            }, 
            {
                "PMID": "14966405", 
                "citation": "Giese T, Zeier M, Schemmer P, Uhl W, Schoels M, Dengler T, Buechler M, Meuer S. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004 Feb 15;77(3):339-44."
            }, 
            {
                "PMID": "18192906", 
                "citation": "Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation. 2008 Jan 15;85(1):15-21. doi: 10.1097/01.tp.0000296824.58884.55."
            }, 
            {
                "PMID": "20463649", 
                "citation": "Sommerer C, Zeier M, Meuer S, Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation. 2010 Jun 15;89(11):1417-23. doi: 10.1097/TP.0b013e3181dc13b6."
            }, 
            {
                "PMID": "16316335", 
                "citation": "Hartmann B, Schmid G, Graeb C, Bruns CJ, Fischereder M, Jauch KW, Heeschen C, Guba M. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int. 2005 Dec;68(6):2593-8."
            }, 
            {
                "PMID": "17660033", 
                "citation": "Leogrande D, Teutonico A, Ranieri E, Saldarelli M, Gesualdo L, Schena FP, Di Paolo S. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis. 2007 Aug;50(2):314-25."
            }, 
            {
                "PMID": "19777549", 
                "citation": "Belouski SS, Wilkinson J, Thomas J, Kelley K, Wang SW, Suggs S, Ferbas J. Utility of lyophilized PMA and ionomycin to stimulate lymphocytes in whole blood for immunological assays. Cytometry B Clin Cytom. 2010 Jan;78(1):59-64. doi: 10.1002/cyto.b.20492."
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "1 year (18 months post-transplant) biopsy proven acute rejections episodes", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "1 year (18 months post-transplant) cumulative infectious complications", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "1 year (18 months post-transplant) GFR", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "1 year (18 months post-transplant) allograft survival", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "1 year (18 months post-transplant) patient survival", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}